奥星生命科技发布中期业绩 股东应占溢利2499.9万元 同比增加325.37%

Group 1 - The company, Aoxing Life Science Technology (06118), reported a revenue of 662 million RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 5.57% [1] - The net profit attributable to shareholders was 24.999 million RMB, showing a significant year-on-year increase of 325.37% [1] - The basic earnings per share were reported at 0.05 RMB [1]